Anthony Wierzbicki Gabriel Steg David Paquette Add HDL-Raising Therapy to Maximise Lipid Treatment REFERENCE: Abstract 53, Page 85 Anthony Wierzbicki, St Thomas’s Hospital, London The idea of ad
Anthony Wierzbicki
Gabriel Steg
David Paquette
Add HDL-Raising Therapy to Maximise Lipid Treatment
REFERENCE: Abstract 53, Page 85Anthony Wierzbicki, St Thomas’s Hospital, LondonThe idea of adding nicotinic acid to lipid-lowering therapy for patients at high risk of coronary events – for either secondary or primary prevention – was discussed at the World Congress of Cardiology and the European Society of Cardiology Congress in Barcelona. At a special session entitled: “Beyond Statin Therapy”Anthony Wierzbickitold delegates about the THRIVE trial adding niacin to statin therapy. Peter Goodwin asked him about this and about the earlier studies: ARBITER and HATS which clearly demonstrated the importance of combining HDL-raising therapy along with LDL reduction.
RIO Study Results: Rimonabant Reduces Body Mass and Cuts Cardiovascular Risks
REFERENCE: Abstract 93Gabriel Steg, Hôpital Bichat, ParisMature findings on the use of the weight-loss drug, rimonabant, were presented to the 2006 meeting of the European Society of Cardiology held in Barcelona. Sarah Maxwell askedGabriel Stegfirst about why rimonabant was considered scientifically as a candidate for appetite reduction, and how effective it has proved in the recent RIO series of studies.
Periodontal Inflammation: A Risk Factor for Cardiovascular Disease?
REFERENCE: Abstract 11David Paquette, University of North Carolina, Chapel HillThe idea that inflammation caused by infectious pathogens can cause a significant burden of cardiovascular disease was explored in a symposium at the cardiology congress which looked at periodontal inflammation and its correlation with coronary disease.David Paquettefrom the University of North Carolina in Chapel Hill presented provocative evidence of possible cause and effect which he discussed with Sarah Maxwell.